US Bio Executive Secures $6 Million Stock Options at Once

David Mettley, President of Nasdaq-listed biopharmaceutical company Inhibrx Biosciences, Inc. (INBX), was granted stock options for 50,000 shares of common stock on April 24, exercisable at $129.06 per share and classified as long-term, performance-based equity compensation. Under the grant, 25% of the options vest and become exercisable on April 24, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, contingent upon continued service. The notional value of the award based on the exercise price is approximately $6.45 million (about KRW 9.5 billion), disclosed as a significant equity component of the executive’s long-term incentive package.

On March 19, the company reported its fourth-quarter and full-year 2025 financial results, announcing plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration for its malignant cartilage sarcoma candidate, Ojeqibat (INBRX-109), in early Q2 2026. It also provided a timeline to present key clinical data later that year on label expansions in colorectal cancer and Ewing sarcoma, as well as combination-therapy data for INBRX-106.

Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical developer spun off in 2024 after Inhibrx completed the sale of its alpha-1 antitrypsin deficiency therapy asset, INBRX-101, to Sanofi for up to $2.2 billion. The spin-off inherited the non-INBRX-101 pipeline and associated personnel. The company is advancing its oncology pipeline—centered on its protein-engineering platform products Ojeqibat (INBRX-109) and INBRX-106—with two lead programs currently in clinical trials targeting advanced solid tumors.